
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies is a promising company with positive catalysts expected in the near future, including key regulatory meetings, potential accelerated approval decisions, and monetization of the PRV. The company has a strong pipeline of product candidates and a clear focus on addressing the need for new treatments in osteosarcoma and other solid tumors. The financials show a heavier cost structure due to development and regulatory work, but the company has already secured funding and is well-positioned to meet regulatory milestones. Overall, OS Therapies has a positive outlook due to its promising product pipeline, strong regulatory momentum, and potential for market entry in the second half of 2026.
Bears say
OS Therapies is currently in the clinical stage, with highly ambitious goals and only two drug technologies in preclinical development, leading to high levels of clinical/regulatory and partnership/financial risk for investors. Additionally, the company's focus on a niche market, osteosarcoma, poses a potential commercial risk and the company may face legal and intellectual property risks as they move towards market approval. With a limited pipeline and smaller target market compared to other pharmaceutical companies, OS Therapies may struggle to gain significant market share, leading to potential financial concerns for investors.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares